Co-founder and CEO of CUTISS, Daniela Marino, PhD, talks about her switch from academia to the biotech industry and her 16-year journey developing a first-in-class personalized tissue therapy.

Approval of Enflonsia was based on data from the Phase IIb/III CLEVER trial, which showed a 60.5% reduction in medically ...

Early Phase I results for JNJ-79635322 demonstrated an 86.1% overall response rate in heavily pretreated multiple myeloma ...

Widaplik marks the first and only FDA-approved triple combination medication that can be used as an initial therapy for patients with hypertension who require multiple drugs to reach their blood ...

Ron Lanton, Partner, Lanton Law, outlines how the MFN executive order may face significant legal challenges from the pharmaceutical industry, citing concerns over due process, intellectual property, ...

NBCUniversal Local and Digital Health Networks (DHN) announced a new healthcare marketing platform called The Care Collective ...

FUJIFILM Irvine Scientific will rebrand as FUJIFILM Biosciences effective immediately. The legal name change will not go into ...

The CEO of Connect Biopharma discusses the unique challenges that patients with asthma and COPD face. Pharmaceutical ...

FDA concluded that AXS-14’s New Drug Application was not sufficiently complete for substantive review, citing concerns with ...

Results from the Phase III CORALreef HeFH and CORALreef AddOn studies demonstrated tatistically significant and clinically ...

Results from the Phase II VLA1553-221 trial show that a full dose of Ixchiq demonstrated a 96.5% seroresponse rate in ...

While the medications may reduce diet, the best results will be achieved by building healthy habits alongside the drugs.